Bharat Tewarie - UCB SA Executive Vice President Chief Marketing Officer

UCBJY Stock  USD 58.22  1.22  2.14%   

President

Dr. Bharat Tewarie has served as Executive Vice President, Chief Marketing Officer, Member of the Executive Committee of UCB S.A. since March 2015. He joined the Company in March 2015. He received an MBA from Webster University in 1991, and a Masters degree from Universiteit Utrecht in 1986. He joined UCB with 27 years of experience in the biotech industry. He has acquired worldwide expertise while leading global business unit teams to great success. His past experience in domains such as immunology and neurology are a great match to UCBs core focus areas. His knowledge of markets around the world is also key to helping UCB prepare for future product launches. Trained as a medical doctor, he also has background in multiple aspects of pharmaceutical management, including PL responsibility, business development, sales, global marketing, clinical research and medical affairs. His key positions prior to UCB 2012 2014 EMD Serono Inc. Senior Vice President, Head of the Global Business Franchise Neurology and Immunology and of the Global Business Franchise Medical Devices 2010 2011 Merck Serono SA Senior Vice President, Head of Global Business Unit Fertility Endocrinology 1998 2010. During this timeframe, Bharat held various leadership positions at Serono International SA, Serono Inc and EMD Serono in Endocrinology and Reproductive Health covering areas such as global sales and marketing, US business unit management and business development. Prior to this, he built up his global and local experience with other companies Roche Pharma and Boehringer Ingelheim. since 2015.
Age 57
Tenure 9 years
Professional MarksMBA
Phone32 2 559 99 99
Webhttps://www.ucb.com

UCB SA Management Efficiency

The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 1.97 B in total debt with debt to equity ratio (D/E) of 0.34, which is about average as compared to similar companies. UCB SA ADR has a current ratio of 1.1, suggesting that it may not have the ability to pay its financial obligations in time and when they become due. Debt can assist UCB SA until it has trouble settling it off, either with new capital or with free cash flow. So, UCB SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like UCB SA ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for UCB to invest in growth at high rates of return. When we think about UCB SA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Giovanni GiovannelliPearson PLC ADR
51
Bob WhelanPearson PLC ADR
71
George YancopoulosRegeneron Pharmaceuticals
58
Charles MilsteinVertex Pharmaceuticals
42
Tom WaldronPearson PLC ADR
N/A
Michael PartridgeVertex Pharmaceuticals
N/A
Paul SilvaVertex Pharmaceuticals
51
Lars GreenNovo Nordisk AS
51
Charles WagnerVertex Pharmaceuticals
56
Marion McCourtRegeneron Pharmaceuticals
64
Joseph LaRosaRegeneron Pharmaceuticals
65
Michael AbermanRegeneron Pharmaceuticals
45
Ludovic HelfgottNovo Nordisk AS
50
Kimberly WhiteVertex Pharmaceuticals
N/A
Christopher FenimoreRegeneron Pharmaceuticals
53
Henrik WulffNovo Nordisk AS
54
Doug LangaNovo Nordisk AS
52
Douglas LangaNovo Nordisk AS
58
Jesper BrandgaardNovo Nordisk AS
54
Jesper HoeilandNovo Nordisk AS
54
Peter AnkersenNovo Nordisk AS
N/A
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. UCB S operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 8600 people. UCB SA ADR [UCBJY] is a Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading.

Management Performance

UCB SA ADR Leadership Team

Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee
Detlef Thielgen, CFO and Executive VP
Kay Davies, Independent Director
Dirk Teuwen, VP Corporate Societal Responsibility
Anna Richo, Executive VP and General Counsel
Viviane Monges, Independent Non-Executive Director
Gerhard Mayr, Non-Executive Chairman of the Board
Cyril Janssen, Director
Caroline Vancoillie, Chief Functions
Cedric Rijckevorsel, Director
JeanChristophe Tellier, Chairman of the Executive Committee, CEO
Arnoud Calesberg, Non-Executive Director
Mark McDade, COO and Executive VP
Xavier Michel, Vice President and Secretary General
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee
Bharat Tewarie, Executive Vice President Chief Marketing Officer
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director
Norman Ornstein, Non-Executive Independent Director
Jeff Wren, Executive Vice President Neurology – Patient Value Unit Head
JeanPierre Kinet, Non-Executive Independent Director
Antje Witte, VP of Investor Relations
Alice Dautry, Independent Director
Sandrine CFA, Ex CFO
Harriet Edelman, Non-Executive Independent Director
Ulf Wiinberg, Independent Director
William Silbey, Exec Counsel
Thomas McKillop, Non-Executive Independent Director
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee
France Nivelle, VP Global Communication
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee
Pierre Gurdjian, Independent Director
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board
Iris LoewFriedrich, Executive Vice President Chief Medical Officer
CharlesAntoine Janssen, Non-Executive Director
Pr LowFriedrich, Chief VP
Kirsten LundJurgensen, Ex Solutions
Albrecht Graeve, Non-Executive Independent Director
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee

UCB Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards UCB SA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, UCB SA's short interest history, or implied volatility extrapolated from UCB SA options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UCB SA ADR. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for UCB Pink Sheet analysis

When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Please note, there is a significant difference between UCB SA's value and its price as these two are different measures arrived at by different means. Investors typically determine if UCB SA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UCB SA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.